SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy

SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy is a phase 3, randomised interventional study registered as NCT06946420 by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, with a registry enrolment figure of 108 participants, started 2025-01-10 and due to reach its primary completion in 2030-01-10. Interventions recorded: SBRT or RT on primary pancreatic and/or metastatic distant lesions before chemotherapy; Standard systemic therapy (chemotherapy) without RT/SBRT. Conditions listed: Radiation Therapy; SBRT; Pancreatic Cancer Metastatic. Primary outcome: Absence of symtomps. Pancreatic eligibility wording from the registry: "* Patients diagnosed with pancreatic cancer, metastatic, candidate for first-line treatment standard systemic; either newly diagnosed in metastatic stage or first progression to metastasis". Sites: Italy. No results are recorded here; the registry entry is the source.